KarMMa-3 Subgroup Analysis in Older Patients with Relapsed/Refractory Multiple Myeloma Treated with Idecabtagene Vicleucel

Key Points

• Older patients demonstrate significant treatment responses, enhancing outcomes in relapsed refractory multiple myeloma.
• Clinical outcomes indicate promising efficacy with idecabtagene vicleucel observed in specific age groups.
• Subgroup analysis was performed focusing on older individuals receiving the novel treatment in a clinical setting.
• Findings suggest that age should be considered when evaluating treatment options for multiple myeloma patients.